首页|血清CCL-20、PDGF-BB、CYFRA21-1水平对NSCLC患者靶向治疗效果的预测价值

血清CCL-20、PDGF-BB、CYFRA21-1水平对NSCLC患者靶向治疗效果的预测价值

扫码查看
目的 分析血清趋化因子配体 20(CCL-20)、血小板源性生长因子BB(PDGF-BB)、细胞角化素蛋白片段19(CYFRA21-1)对非小细胞肺癌(NSCLC)患者靶向治疗效果的预测价值.方法 选取进行靶向治疗的 79 例中晚期NSCLC患者,均持续治疗2 月,评价患者近期疗效.收集患者一般临床资料,并于治疗前后分别检测患者血清趋化因子CCL-20、PDGF-BB、CYFRA21-1 水平,比较不同疗效患者间相关资料差异,分析影响疗效的因素,并利用ROC分析血清趋化因子CCL-20、PDGF-BB、CYFRA21-1 水平预测近期疗效的价值.结果 79 例中晚期NSCLC患者均完成2 个月的靶向治疗,治疗总有效率为45.57%(36/79).有效组共36 例,无效组(SD +PD)共43 例,2 组年龄、性别、病理类型相较无差异(P>0.05);有效组TNM ⅢB期、高分化占比高于无效组(P<0.05);有效组治疗前后血清 CCL-20、PDGF-BB、CY-FRA21-1 水平均低于无效组(P<0.05).多因素Logistic回归分析结果显示,治疗前血清CCL-20、PDGF-BB、CYFRA21-1水平为影响疗效的独立因素(OR =9.574,10.903,11.156,P<0.05).ROC分析结果显示,治疗前血清CCL-20、PDGF-BB、CYFRA21-1 水平均具有预测临床疗效的价值(AUC =0.775,0.896,0.669,P<0.05).结论 中晚期NSCLC患者血清CCL-20、PDGF-BB、CYFRA21-1 水平与靶向治疗效果有关,可作为靶向治疗近期疗效评估的辅助性指标.
Predictive Value of Serum CCL-20,PDGF-BB and CYFRA21-1 for Curative Effect of Targeted Therapy in NSCLC Patients
Objective To analyze the predictive value of serum chemokine ligand 20(CCL-20),platelet-derived growth factor BB(PDGF-BB)and cytokeratin fragment 19(CYFRA21-1)for curative effect of targeted therapy in patients with non-small cell lung cancer(NSCLC).Methods A total of 79 patients with advanced NSCLC underwent targeted therapy were enrolled.All were continuously treated for 2 months to evaluate the short-term curative effect.The general clinical data of patients were collect-ed.Before and after treatment,levels of serum CCL-20,PDGF-BB and CYFRA21-1 were detected.The differences of relevant data in patients with different curative effect were compared.The influencing factors of curative effect were analyzed.The predictive value of serum CCL-20,PDGF-BB and CYFRA21-1 for short-term curative effect was analyzed by ROC curves.Results The 2-month targeted therapy was completed in all the 79 patients with advanced NSCLC,and the total response rate of treatment was 45.57%(CR +PR,36/79).There were 36 cases in effective group and 43 cases in ineffective group(SD + PD).There was no significant difference in age,gender or pathological types between the 2 groups(P>0.05).The proportions of TNM staging at stage ⅢB and high differentiation in effective group were higher than those in ineffective group(P<0.05).Before and after treat-ment,levels of CCL-20,PDGF-BB and CYFRA21-1 in effective group were lower than those in ineffective group(P<0.05).The results of multivariate Logistic regression analysis showed that serum CCL-20,PDGF-BB and CYFRA21-1 were independent influ-encing factors of curative effect(OR =9.574,10.903,11.156,P<0.05).The results of ROC curves analysis showed that CCL-20,PDGF-BB and CYFRA21-1 were all of predictive value for clinical curative effect(AUC =0.775,0.896,0.669,P<0.05).Conclusion The levels of serum CCL-20,PDGF-BB and CYFRA21-1 are related curative effect of targeted therapy in patients with advanced NSCLC,which can be applied as auxiliary indexes to evaluate the short-term curative effect of targeted therapy.

Non-small cell lung cancer(NSCLC)Serum chemokine CCL-20Platelet-derived growth factor BB(PDGF-BB)Cytokeratin fragment 19(CYFRA21-1)Targeted therapyShort-term curative effect

赵志娟、仝岩、李文博、冯慧洁

展开 >

450000 河南中医药大学第一附属医院

非小细胞肺癌 血清趋化因子CCL-20 血小板源性生长因子BB 细胞角化素蛋白片段19 靶向治疗 近期疗效

2024

实用癌症杂志
江西省肿瘤医院 江西省肿瘤研究所

实用癌症杂志

影响因子:1.241
ISSN:1001-5930
年,卷(期):2024.39(4)
  • 15